MUC1-Tn is overexpressed in T-cell acute lymphoblastic leukemia (T-ALL) and serves as an effective target for CAR T cell therapy.
Linperlisib, a selective PI3Kδ inhibitor, enhances MUC1-Tn CAR T cell cytotoxicity and persistence both in vitro and in xenograft T-ALL models.
Linperlisib prevents CAR T cell exhaustion through suppression of the EGR1/DUSP2 signaling axis and promotes mitochondrial fusion and respiratory function.
This combination approach offers a promising strategy to overcome CAR T cell target-mediated fratricide and functional exhaustion in T-ALL treatment.
